Idioma:

The impact of immunosenescence on the efficacy of immune checkpoint inhibitors in melanoma patients: a meta-analysis

Li, Ping ; Yang, Xuefang ; Feng, Yumiao ; Wu, Lijuan ; Ma, Wei ; Ding, Gaozhong ; Wei, Yun ; Sun, Lan

OncoTargets and therapy, 2018-01, Vol.11, p.7521-7527 [Periódico revisado por pares]

New Zealand: Dove Medical Press Limited

Texto completo disponível

Citações Citado por

Enviar para

Título:
The impact of immunosenescence on the efficacy of immune checkpoint inhibitors in melanoma patients: a meta-analysis
Autor: Li, Ping ; Yang, Xuefang ; Feng, Yumiao ; Wu, Lijuan ; Ma, Wei ; Ding, Gaozhong ; Wei, Yun ; Sun, Lan
Assuntos: Age groups ; Aging ; Analysis ; Antigens ; Bias ; Cancer therapies ; Chemotherapy ; Clinical medicine ; Clinical trials ; Collaboration ; Cytotoxicity ; Elderly patients ; Immune checkpoint ; Immune checkpoint inhibitor ; Immune response ; Immune system ; Immunosenescence ; Immunotherapy ; Ipilimumab ; Lung cancer ; Melanoma ; Meta-analysis ; Metastasis ; Nivolumab ; Operating systems (Software) ; Original Research ; Patients ; PD-1 ; PD-1 protein ; Statistical analysis ; Systematic review ; Tumors
É parte de: OncoTargets and therapy, 2018-01, Vol.11, p.7521-7527
Notas: ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Descrição: Immunosenescence, the age-related decline of immunity, affects the immune responses of melanoma patients. Through immune responses, immune checkpoint inhibitors (ICIs) exert their antitumor robustness. In different ages of melanoma patients, especially the older patients, the effectiveness of ICIs remains unclear. It is still controversial whether ICIs should be used in treating older patients. The authors included clinical trials of ICIs in older and younger patients. The authors used hazard ratio (HR) and 95% CI of overall survival (OS). From four phase III randomized clinical trials 2,251 melanoma patients were included. We found that ICIs significantly prolonged the OS for melanoma patients in both younger (HR, 0.71; 95% CI, 0.60-0.82; <0.001) and older groups (HR, 0.62; 95% CI, 0.41-0.83; <0.001) compared with controls. Anti-programmed death-1 (PD-1) agents appeared to be more efficient in older melanoma patients (HR, 0.34; 95% CI, 0.14-0.53) versus younger patients (HR, 0.52; 95% CI, 0.26-0.78). ICIs significantly prolonged the OS for melanoma patients in both younger and older groups than controls. Anti-PD-1 agents were more efficient in older melanoma patients versus younger patients. ICIs could be used for older melanoma patients.
Editor: New Zealand: Dove Medical Press Limited
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

The impact of immunosenescence on the efficacy of immune checkpoint inhibitors in melanoma patients: a meta-analysis

Li, Ping ; Yang, Xuefang ; Feng, Yumiao ; Wu, Lijuan ; Ma, Wei ; Ding, Gaozhong ; Wei, Yun ; Sun, Lan

New Zealand: Dove Medical Press Limited

Buscando em bases de dados remotas. Favor aguardar.